IDEXX Cancer Dx testing provides accurate detection of biomarkers specific for lymphoma in canine serum and whole blood. B-cell vs. T-cell phenotype classification will be provided with positive results as available at no additional cost.

IDEXX Cancer Dx testing provides two indications, both for canine lymphoma:

• Aid in diagnosis: IDEXX Cancer Dx testing can be performed on dogs in which lymphoma is suspected, whether that be due to a physical examination abnormality, blood work abnormality or report of illness or change in behaviour at home.
• Screening: In early studies, IDEXX Cancer Dx testing has the potential to detect lymphoma up to 2 months in advance of the onset of clinical signs.¹ This would be most appropriately used in senior dogs (aged 7 years and older) and at-risk breeds aged 4 and older.

At-risk dogs include dogs of all breeds aged 7 or older and dogs of breeds at increased risk for cancer aged 4 or older. These dog breeds have an increased risk for lymphoma: Labrador retriever, rottweiler, Doberman pinscher and English bulldog. Dog breeds at increased risk for cancer include those above along with these: golden retriever, French bulldog, beagle, boxer, miniature schnauzer, Bernese mountain dog, flat-coated retriever, Scottish terrier and bullmastiff.

The specimen requirement for IDEXX Cancer Dx testing is 1 mL of EDTA whole blood and 2 mL of serum when run as a standalone. When run in or with a profile that includes chemistry and CBC, IDEXX Cancer Dx testing is run using a portion of the submitted specimen, which should be at least 1 mL whole blood/2 mL serum (or any further profile requirement). When submitted with a profile request, a separate pair of tubes is NOT required for IDEXX Cancer Dx testing.

Results will be reported as either ‘consistent with lymphoma’ or ‘not consistent with lymphoma’. If a result is unable to be obtained on the specimen submitted, the customer will be notified appropriately within their results view.